|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
injectable
|
|
gptkbp:bioavailability
|
40%
|
|
gptkbp:brand
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:CASNumber
|
139755-83-2
|
|
gptkbp:category
|
vasodilator
erectile dysfunction drug
|
|
gptkbp:chemicalFormula
|
C22H30N6O4S
|
|
gptkbp:contraindication
|
nitrate medication
severe cardiovascular disorders
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredIn
|
1989
|
|
gptkbp:drugClass
|
phosphodiesterase inhibitor
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1989
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sildenafil
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
nitrates
alpha-blockers
CYP3A4 inducers
|
|
gptkbp:IUPACName
|
gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
|
|
gptkbp:KEGGID
|
D08514
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
PDE5 inhibitor
|
|
gptkbp:MedlinePlusID
|
a699015
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
474.6 g/mol
|
|
gptkbp:patentExpired
|
2013
|
|
gptkbp:pregnancyCategory
|
B (US)
B1
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
5212
CHEMBL192
DB00203
|
|
gptkbp:riskFactor
|
priapism
sudden hearing loss
sudden vision loss
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
headache
nasal congestion
dyspepsia
flushing
visual disturbances
|
|
gptkbp:UNII
|
3M7OB98Y7H
|
|
gptkbp:usedFor
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:bfsParent
|
gptkb:148553-50-8
gptkb:169590-42-5
gptkb:119302-91-9
gptkb:136817-59-9
|
|
gptkbp:bfsLayer
|
7
|